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Endogenous formation of N-nitroso compounds (NOCs), which are known animal carcino-
gens, could contribute to human carcinogenesis but deﬁnitive evidence is still lacking. To
investigate the relevance of NOCs in human colorectal cancer (CRC) development, we ana-
lyzed whole genome gene expression modiﬁcations in human colon biopsies in relation to
fecal NOC exposure. We had a particular interest in patients suffering from intestinal
inﬂammation as this may stimulate endogenous NOC formation, and consequently predis-
pose to CRC risk. Inﬂammatory bowel disease (IBD) patients diagnosed with ulcerative coli-
tis and irritable bowel syndrome patients without inﬂammation, serving as controls, were
therefore recruited. Fecal NOC were demonstrated in the majority of subjects. By associat-
ing gene expression levels of all subjects to fecal NOC levels, we identiﬁed a NOC exposure-
associated transcriptomic response that suggests that physiological NOC concentrations
may potentially induce genotoxic responses and chromatin modiﬁcations in human colon
tissue, both of which are linked to carcinogenicity. In a network analysis, chromatin mod-
iﬁcations were linked to 11 signiﬁcantly modulated histone genes, pointing towards a
possible epigenetic mechanism that may be relevant in comprehending NOC-induced car-
cinogenesis. In addition, pro-inﬂammatory transcriptomic modiﬁcations were identiﬁed in
visually non-inﬂamed regions of the IBD colon. However, fecal NOC levels were slightly but
not signiﬁcantly increased in IBD patients, suggesting that inﬂammation did not strongly
stimulate NOC formation. We conclude that NOC exposure is associated with gene expres-
sion modiﬁcations in the human colon that may suggest a potential role of these com-
pounds in CRC development.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.1. Introduction
N-nitroso compounds (NOCs) have long been suspected
to play a role in human carcinogenesis since many NOCsx: +31 43 3884146.
l (D.G.A.J. Hebels).
nder the Elsevier OA license.possess genotoxic and mutagenic properties and are
known animal carcinogens [1,2]. Most NOCs have therefore
been classiﬁed as probable or possible human carcinogens
by the International Agency for Research on Cancer [3].
Human exposure to NOCs occurs almost entirely through
food and endogenous nitrosation of NOC precursors in
the gastrointestinal tract [4] and, following absorption into
2 D.G.A.J. Hebels et al. / Cancer Letters 309 (2011) 1–10the bloodstream, NOCs may have deleterious effects in
many tissues. Epidemiological studies have indeed associ-
ated human (endogenous) NOC exposure to several types
of cancer, including esophagus, stomach, colorectal and
bladder cancer [5–8], but proof of a causal relation be-
tween NOCs and human cancer is still missing.
In several recent in vitro studies in a human colon cell
line, we have explored the transcriptomic effects of NOCs
in relation to their genotoxicity in order to elucidate poten-
tially important gene expression modiﬁcations that may
play a role in the carcinogenic process [9,10]. We identiﬁed
many NOC-modulated biological pathways that regulate
crucial processes with regard to carcinogenesis, such as
DNA damage control, proliferation, and differentiation.
These modulations may act in concert with the DNA-dam-
aging properties of NOCs and increase the carcinogenic risk
associated with exposure.
As a result of endogenous nitrosation processes in the
intestinal lumen, highest NOC exposure levels may occur
in the human colon and therefore the colon represents an
important target tissue for investigating molecular effects
of NOC exposure. Furthermore, there are indications that
colon inﬂammation stimulates endogenous NOC formation
since inducible nitric oxide synthase (iNOS) activity, as
found in inﬂammatory bowel disease (IBD) patients [11],
is associated with an excess production of nitrosating
agents, such as NO, nitrogen oxides, and nitrite [12], which
in turn generate NOCs from precursors in the diet [13,14].
Individuals suffering from IBD therefore present an inter-
esting population to study NOC exposure-related adverse
effects, especially since this group is at increased risk of
colorectal cancer (CRC) [15,16]. We considered a global
analysis of gene expression modiﬁcations a powerful tech-
nology for providing more insight in NOC-mediated
modes-of-action in relation to possible pre-carcinogenic
events in the human colon.
We therefore hypothesize that NOC exposure in the
human colon results in gene expression modiﬁcations in
colon tissue that indicate carcinogenic properties of these
compounds in humans. To investigate this, we studied
transcriptomic differences in colon biopsies obtained from
colon patients in relation to fecal NOC levels as a marker of
colonic NOC exposure, and compared IBD patients with
irritable bowel syndrome (IBS) control subjects. With this
study, we aimed to identify changes in molecular path-
ways which may contribute to the carcinogenic process
in the human colon.
2. Material and methods
2.1. Subjects and study design
Subjects were recruited in the Netherlands at the
Department of Gastroenterology in the Orbis Medical Cen-
ter in Sittard and the Academic Hospital Maastricht. A total
of 44 IBD patients (29 male, 15 female, mean age 48.8 ±
14.4, range 23–81 years) and 36 control patients diagnosed
with IBS (15 male, 21 female, mean age 56.2 ± 15.3, range
21–78 years) were included. Eligible IBD patients had a his-
tory of ulcerative colitis with a moderate exacerbation of
the inﬂammatory state at the time of inclusion as basedon an anamnesis and the scheduled colonoscopy. Crohn’s
disease patients were excluded from participation as well
as patients who had to be admitted to hospital or had a his-
tory of colorectal adenomas. Only IBS patients proven free
(as evaluated by colonoscopy) from colorectal disease and
other gastrointestinal disorders were included as controls.
Food diaries were recorded for three consecutive days after
which subjects collected a feces sample. This was immedi-
ately frozen (20 C) upon collection. A subset of both pa-
tient groups (19 IBD and 13 IBS) also participated in a
colonoscopic examination during which six biopsies were
taken frommucosal tissue in visually non-inﬂamed regions
of the sigmoid or descending colon which were immedi-
ately frozen in liquid nitrogen and stored at 80 C until
use. The colonoscopy was performed as part of either sur-
veillance or suspected gastrointestinal disorders. Use of
additional anti-inﬂammatory medication in IBD patients
for treating the exacerbated colon inﬂammation was post-
poned until the end of the study. During 3 days before the
colonoscopy, subjects followed their normal dietary habits,
with a few modiﬁcations. Namely, to keep nitrate intake
among subjects similar, participants were asked to use
low-nitrate mineral water when preparing food or drinks
and to avoid vegetables with high nitrate concentrations,
such as spinach, lettuce, and celery. A high fruit consump-
tion, especially fruit rich in vitamin C, and use of vitamin
supplements also had to be restricted to avoid inhibiting
endogenous nitrosation [17].
This study was approved by the Medical Ethical Com-
mittee Atrium Orbis Zuyd and Clinical Trial Center Maas-
tricht (registration number NL13359.096.06). Written
informed consent was obtained from the participants prior
to the start of the study.
2.2. Fecal apparent total nitroso compound determination
Apparent total nitroso compounds (ATNC) were ana-
lyzed in feces by thermal energy analysis as described pre-
viously [18], using an Ecomedics CLD88 Exhalyzer
(Ecomedics, Duernten, Switzerland). In short, fecal mate-
rial was diluted 1:5 in ultrapure water and homogenized
for 20 min. Thereafter, 500 ll of a 5% (wt/vol) sulfamic acid
solution was added to remove nitrite and samples were in-
jected into a purge vessel kept at 60 C and ﬁlled with a
standard tri-iodide reagent (38 mg I2 was added to a solu-
tion of 108 mg KI in 1 ml water; to this mixture, 13.5 ml
glacial acetic acid was added) to determine ATNC. Results
are presented as nmol/g feces.
2.3. Microarray hybridization and data analysis
From each subject, three biopsies were separately dis-
solved in QIAzol (Qiagen, Venlo, The Netherlands) using
a tissue disruptor, and subsequently pooled. RNA was iso-
lated according to the manufacturer’s protocol (average
RNA integrity number: 7.1 ± 1.0). Microarray hybridization
was performed as described previously with some modiﬁ-
cations [10]. In short, dye-labeled cRNA (Cy3) was synthe-
sized following the one-color labeling protocol supplied by
the manufacturer (Agilent Technologies, Amstelveen, The
Netherlands). Samples were hybridized on Agilent 4x44K
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microarray slides, using settings described before [10],
bad and empty spots were ﬂagged using GenePix Pro (ver-
sion 6.0, Molecular Devices, Sunnyvale, CA). For each spot,
mean local background intensity was subtracted from
mean signal intensity, and spots with a mean net signal
intensity <10.0 were omitted from analysis. Quality control
was performed in R (version 2.10.1, The R Foundation for
Statistical Computing, Vienna, Austria). Quantile normali-
zation and data processing was performed in ArrayTrack
(version 3.4, NCTR, Jefferson, AR). Log2 transformed spot
intensities were used for further analyses.
For Spearman’s rank correlation analyses gene expres-
sion data were correlated with ATNC levels. Only genes
present in at least 70% of subjects (both IBD and IBS pa-
tients) were used without further pre-selection. Prior to
correlation analysis, missing values were imputed in Gene-
Pattern by ﬁnding the k nearest neighbors (k set to 15),
using a Euclidean metric. Correlation analyses were per-
formed in the Gene Expression Proﬁle Analysis Suite (GE-
PAS, http://gepas.bioinfo.cipf.es/). Signiﬁcantly correlating
genes (p < 0.05) were further analyzed in MetaCore™
(GeneGo, San Diego, CA). A gene network based on a select
number of genes was created in MetaCore using Dijkstra’s
shortest paths algorithm.
GenePattern version 3.1 (http://www.broad.mit.edu/
cancer/software/genepattern/) was used for three-dimen-
sional principal component analysis (PCA) of the gene
expression intensities of all subjects. With ArrayTrack
modulated genes between IBD and IBS groups were identi-
ﬁed by combining a log ratio ranking (absolute log2 ratio
>0.5) with a non-stringent p-value cut-off (two-tailed
Welch t-test, p < 0.05), as suggested by Shi et al. [19]. The
false discovery rate at this p-value cut-off was 3%, which
was calculated using Storey’s q-value approach [20]. Fur-
ther ﬁltering was performed by selecting only those genes
that were present in at least 70% of subjects (both IBD and
IBS patients). Genes were subsequently imported in Meta-
Core to identify the involvement of differentially expressed
genes in speciﬁc cellular GeneGo pathways or Gene Ontol-
ogy (GO) processes. Pathways with a p < 0.05 were consid-
ered signiﬁcantly modulated.
2.4. Fecal calprotectin
Calprotectin (in lg/g feces) as a marker of chronic
inﬂammation was determined as described previouslyTable 1
Population characteristics, fecal ATNC, and calprotectin levels in IBS controls and
All subjects
IBS IBD
n = 36 n = 44
Age (years) [range] 56.2 ± 15.3 [21–78] 48.8 ± 14
Gender (male/female) 15/21 29/15
ATNC above detection limit 28 of 36 37 of 44
ATNC (nmol/g feces) 7.4 ± 8.1 10.1 ± 10
Calprotectin (lg/g feces) 11.0 ± 16.8 37.0 ± 26
a Signiﬁcantly higher in IBD group compared to IBS group (p < 1  107, Mann
b Signiﬁcantly higher in IBD group compared to IBS group at p < 0.001 (Stude[21]. In short, approximately 100 mg of wet feces was di-
luted 50 times in extraction buffer, homogenized, and cen-
trifuged after which the supernatant was used for analysis
of calprotectin using a standard ELISA kit (Hycult Biotech,
Uden, The Netherlands) according to the manufacturer’s
instructions.
2.5. Statistical analysis
Results are presented as mean ± SD. Normality of data
was tested using the Kolmogorov–Smirnov test. Potential
differences between groups were assessed using the
Mann–Whitney U test, or Student’s t-test (for equal or un-
equal variances, as based on Levene’s test) depending on
the normality of data. Spearman’s rank test was used for
correlation analyses.
The gene expression data discussed in this publication
have been deposited in NCBI’s (National Center for Bio-
technology Information) Gene Expression Omnibus (GEO)
and are available through GEO Series accession number
GSE25220 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi
?acc=GSE25220).
3. Results
3.1. Endogenous NOC formation and associated gene expression modiﬁcations
Fecal ATNC levels could be demonstrated above limits of detection
(0.01 nmol/g feces) in 65 out of a total of 80 subjects (Table 1). To inves-
tigate the transcriptomic response in the colon biopsies speciﬁcally
linked to this NOC formation in more detail we performed a Spearman’s
rank correlation analysis between ATNC levels and log2 gene expression
intensities. Signiﬁcantly correlating genes (p < 0.05) were subsequently
analyzed for their involvement in GeneGo pathways and GO processes.
In Table 2, all GeneGo pathways and the top 10 of a total of 153 GO pro-
cesses signiﬁcantly associated (p < 0.05) with ATNC levels are presented.
The most strongly represented cellular process was transport with two
pathways involved in clathrin-coated vesicle formation and macropino-
cytosis. Most importantly in view of the established genotoxic properties
of NOCs, a DNA damage repair pathway appeared associated with ATNC
levels while the remaining pathways share relevant and signiﬁcantly
correlating genes that are involved in signaling pathways related to cell
cycle regulation and apoptosis, such as the RAC1 G-protein signaling
pathway.
The top 10 of GO processes signiﬁcantly associated with ATNC levels
were mostly involved in nucleosome/chromatin assembly which may re-
late to epigenomic phenomena. In Fig. 1, the closest interactions between
the signiﬁcantly correlating genes in the Chromatin assembly GO process
are shown. The network contains 14 genes that signiﬁcantly correlate
(in most cases positively) with ATNC levels, consisting of 11 histone
genes, the heterochromatin protein 1 binding protein (HP1-BP74) gene,
centromere protein V (PRR6), and SWI/SNF related, matrix associated,IBD patients shown for all subjects and the biopsy subgroup.
Biopsy subjects
IBS IBD
n = 13 n = 19
.4 [23–81] 55.5 ± 13.1 [25–69] 49.8 ± 12.1 [29–72]
7/6 15/4
12 of 13 16 of 19
.5 7.2 ± 6.1 10.5 ± 11.2
.1a 12.0 ± 17.0 38.8 ± 21.0b
–Whitney U test).
nt’s t-test).
Table 2
GeneGo pathways and the top 10 of GO processes signiﬁcantly associated with ATNC levels as found by MetaCore analysis of signiﬁcantly correlating
genes in biopsy subjects of IBD and IBS groups combined (n = 32).
Cellular process Pathways involved Genes present (signiﬁcant/total) % Genesa p-Value
GeneGo pathways
Cytoskeleton remodeling RalA regulation pathway 4/23 17 0.023
Development PIP3 signaling in cardiac myocytes 4/27 15 0.040
DNA damage NHEJ mechanisms of DSBs repair 4/14 29 0.004
G-protein signaling RAC1 in cellular process 5/22 23 0.003
Signal transduction AKT signaling 4/27 15 0.040
Transport Clathrin-coated vesicle cycle 12/55 22 0.000
Macropinocytosis regulation by growth factors 5/36 14 0.029
GO process name Genes present (signiﬁcant/total) % Genesa p-Value
GO processes
Chromatin assembly 14/69 20 0.0000
mRNA metabolic process 39/357 11 0.0000
Chromatin assembly or disassembly 17/103 17 0.0001
Nucleosome assembly 13/66 20 0.0001
Protein–DNA complex assembly 14/76 18 0.0001
Nucleosome organization 13/73 18 0.0002
Cellular biopolymer catabolic process 56/625 9 0.0003
DNA packaging 15/100 15 0.0004
RNA metabolic process 74/898 8 0.0005
RNA processing 48/523 9 0.0005
The false discovery rates for the GeneGo pathways and GO processes presented here were below 17% and 13% respectively.
a Percentage of signiﬁcantly correlated genes compared to the total number of genes in the pathway or process.
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Most of these genes are involved in the epigenetic regulation of gene
expression which thus suggests that NOCs might inﬂuence this process.
3.2. Differences between IBD and IBS patients
Although the average ATNC level is approximately 40% higher in IBD
patients than in IBS controls, inter-individual variation is high (Table 1).
As a result, no signiﬁcant difference was found in ATNC between controlsFig. 1. A network analysis of genes in the Chromatin assembly GO process show
levels in both biopsy patients groups. Signiﬁcantly correlating genes are designa
indicated with small red and blue circles, respectively.and IBD patients in the total group (p = 0.261) or biopsy subgroup
(p = 0.348). There also were no signiﬁcant differences between genders
(p > 0.428). To check whether IBD patients did display a higher level of
inﬂammation we measured fecal calprotectin levels. IBD patients indeed
had a signiﬁcantly higher fecal calprotectin level than control patients, in
both the total group and the biopsy subjects group (p < 1  107 and
p < 0.001, respectively), indicating a higher level of inﬂammation (Table
1). There were no signiﬁcant differences between genders (p > 0.735).
ATNC levels were not correlated with calprotectin as a marker ofing the shortest paths between genes signiﬁcantly correlating with ATNC
ted by a blue circle in the background. Positive and negative correlation is
Table 3
Reported average daily dietary intake before biopsy sampling in IBS
controls and IBD patients.
Dietary intake
(average/day)
IBS controls, n = 36 IBD patients, n = 44
Energy (kcal) 1818 ± 469 2068 ± 593
Protein (g) 70.5 ± 19.6 79.3 ± 20.9
Animal protein (g) 24.0 ± 16.4 28.7 ± 18.2
Total fat (g) 67.7 ± 21.4 89.4 ± 34.3a
Saturated fat (g) 26.0 ± 9.7 32.3 ± 11.5b
Cholesterol (mg) 170 ± 79.9 228 ± 113b
Carbohydrates (g) 219 ± 66.6 214 ± 60.6
Fibers (g) 17.9 ± 5.8 19.1 ± 5.9
Alcohol (g) 6.6 ± 10.0 10.7 ± 14.6
Water (g) 1803 ± 523 1856 ± 566
Sodium (mg) 2922 ± 774 3318 ± 921
Potassium (mg) 2603 ± 658 2769 ± 812
Calcium (mg) 705 ± 297 813 ± 279
Magnesium (mg) 264 ± 63.3 275 ± 73.0
Iron (mg) 10.2 ± 2.6 11.1 ± 3.5
Selenium (lg) 36.7 ± 12.4 49.9 ± 34.8
Zinc (mg) 7.5 ± 2.3 9.0 ± 2.6b
Folic acid (lg) 139 ± 45.4 165 ± 45.1b
Vitamin A (lg) 765 ± 469 938 ± 532
Vitamin B1 (mg) 1.0 ± 0.3 1.1 ± 0.5
Vitamin B2 (mg) 1.0 ± 0.4 1.2 ± 0.4
Vitamin B3 (mg) 14.6 ± 4.3 15.5 ± 6.3
Vitamin B6 (mg) 1.4 ± 0.5 1.5 ± 0.5
Vitamin B12 (lg) 2.9 ± 1.7 4.2 ± 3.1b
Vitamin C (mg) 51.2 ± 32.1 62.4 ± 43.7
Vitamin D (lg) 3.5 ± 1.8 4.4 ± 3.2
Vitamin E (mg) 13.2 ± 8.4 14.0 ± 8.8
a Signiﬁcantly different between IBS and IBD groups at p < 0.01 but not
after correction for gender (Student’s t-test).
b Signiﬁcantly different between IBS and IBD groups at p < 0.05 but not
after correction for gender (Student’s t-test).
Fig. 2. PCA plot of the microarray-based expression proﬁles showing a separation
by three principal components (PCs) accounting for 24%, 13%, and 9% of variatio
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tween the highest versus lowest ATNC patients (IBS or IBD) also did not
show any speciﬁc group clustering (results not shown). This indicates
that there was no strong association between endogenous nitrosation
and inﬂammatory conditions in the colon.
The results of the food diary analysis are presented in Table 3. Average
daily intake during the 3 days prior to the biopsy sampling was not signif-
icantly different between IBS controls and IBD patients, except for total
and saturated fat, cholesterol, zinc, folic acid, and vitamin B12. However,
as shown in Table 1, the male/female ratio was not equal between these
groups and after correcting for gender, the differences in food intake were
no longer found to be signiﬁcant.3.3. Differential gene expression between IBD patients and controls
We subsequently determined whether gene expression proﬁles in
visually non-inﬂamed colon tissue provide any additional information
on differences in a possible carcinogenic risk between IBD and IBS pa-
tients, regardless of ATNC levels. The PCA plot in Fig. 2 shows that IBS con-
trols group separately from IBD patients indicating distinct proﬁles at the
transcriptomic level. These differences were further investigated by
selecting signiﬁcantly modulated genes (p < 0.05, Welch t-test) between
the groups at an absolute log2 ratio cut-off value of 0.5. A total of 2266
genes met this criterion and were further investigated in MetaCore. The
results of this analysis are presented in Table 4 and show a high number
of signiﬁcantly modulated pathways (p < 0.05) involved in the immune
response and in development. Most developmental pathways found to
be modiﬁed are involved in the JAK/STAT signaling cascade and growth
hormone signaling, while the immune response pathways are mostly in-
volved in cytokine signaling and the complement signaling system.
Strongly up and down regulated genes in the modiﬁed immune response
pathways clearly indicate a pro-inﬂammatory state in IBD patients com-
pared to controls (results not shown). Signiﬁcantly modulated genes in
the developmental pathways are also mostly involved in downstream sig-
naling cascades linked to the immune response. The remaining modiﬁed
pathways/processes were involved in arginine metabolism, blood coagu-
lation, cell adhesion, and cytoskeleton remodeling.between IBD patients (black) and IBS controls (gray). Data were described
n.
Table 4
Signiﬁcantly modulated GeneGo pathways grouped by cellular process as found by MetaCore analysis of genes differentially regulated between IBD (n = 19) and
IBS (n = 13) patients.
Cellular process Pathways involved Genes present (signiﬁcant/total) % Genesa p-Value
Amino acid metabolism (L)-Arginine metabolism 6/23 26 0.017
Blood coagulation Blood coagulation 10/24 42 0.000
Cell adhesion ECM remodeling 9/35 26 0.004
Cell–matrix glycoconjugates 6/22 27 0.014
Cytoskeleton remodeling Neuroﬁlaments 4/14 29 0.036
Development Angiotensin signaling via STATs 7/15 47 0.000
Leptin signaling via JAK/STAT and MAPK cascades 7/19 37 0.001
Growth hormone signaling via STATs and PLC/IP3 8/27 30 0.003
Thrombopoetin signaling via JAK-STAT pathway 6/17 35 0.003
PDGF signaling via STATs and NF-kB 5/18 28 0.022
EPO-induced Jak-STAT pathway 7/31 23 0.023
Prolactin receptor signaling 8/38 21 0.023
GM-CSF signaling 7/32 22 0.027
Hypoxia-induced EMT in cancer and ﬁbrosis 3/8 38 0.033
Transcription regulation of granulocyte development 5/20 25 0.034
EPO-induced PI3K/AKT pathway and Ca(2+) inﬂux 5/20 25 0.034
Growth hormone signaling via PI3K/AKT and MAPK cascades 7/35 20 0.042
Immune response IL-17 signaling pathways 14/37 38 0.000
Oncostatin M signaling via JAK-Stat in human cells 8/14 57 0.000
Antiviral actions of interferons 10/24 42 0.000
IL-23 signaling pathway 6/10 60 0.000
Alternative complement pathway 9/23 39 0.000
IL-27 signaling pathway 7/15 47 0.000
MIF-mediated glucocorticoid regulation 7/16 44 0.000
IFN alpha/beta signaling pathway 7/18 39 0.001
Bacterial infections in normal airways 9/32 28 0.002
Cytokine production by Th17 cells in CF 7/21 33 0.002
Oncostatin M signaling via MAPK in human cells 8/27 30 0.003
Lectin induced complement pathway 7/22 32 0.003
Classical complement pathway 7/22 32 0.003
IL-10 signaling pathway 6/18 33 0.005
Bacterial infections in CF airways 9/36 25 0.005
IL-1 signaling pathway 9/36 25 0.005
IL-3 activation and signaling pathway 6/19 32 0.006
Histamine H1 receptor signaling in immune response 7/25 28 0.007
IL-22 signaling pathway 6/20 30 0.008
CD40 signaling 9/41 22 0.012
IL-12 signaling pathway 5/16 31 0.013
IL-12-induced IFN-gamma production 6/22 27 0.014
IFN gamma signaling pathway 8/35 23 0.014
MIF in innate immunity response 6/24 25 0.021
PGE2 signaling in immune response 6/24 25 0.021
Mucin expression in CF via IL-6, IL-17 signaling pathways 5/19 26 0.028
Th1 and Th2 cell differentiation 5/20 25 0.034
Sialic-acid receptors (Siglecs) signaling 3/8 38 0.033
Reproduction GnRH signaling 7/35 20 0.042
Transcription CREM signaling in testis 3/8 38 0.033
The false discovery rate for the GeneGo pathways presented here was below 36% at p-value 0.05 and below 14% at p-value 0.01.
a Percentage of signiﬁcantly modulated genes compared to the total number of genes in the pathway.
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With this study we aimed to investigate gene expres-
sion modiﬁcations hypothetically induced in human colon
tissue in relation to NOC exposure. Since the relevance of
NOCs in human CRC development is still a matter of de-
bate, identifying changes in the expression pattern may
be helpful in assessing the carcinogenic risk in humans.
NOCs, as measured by ATNC, were detected in most fe-
cal samples (Table 1). Thus, by speciﬁcally investigating
genes whose expression values are signiﬁcantly correlated
with individual ATNC levels, it appeared possible to iden-
tify NOC exposure-associated gene expression modula-
tions in most biopsy subjects by pooling data from IBDand IBS patients. The set of genes found to be signiﬁcantly
correlated with ATNC levels was involved in several path-
ways that can be attributed to the well-known genotoxic
properties of NOCs (Table 2). One pathway regulating
DNA repair was identiﬁed in addition to four signaling cas-
cade pathways regulated by members of the Ras superfam-
ily of small GTPases (RALA and RAC1), phosphatidylinositol
(3,4,5)-trisphosphate (PIP3), and serine/threonine protein
kinase AKT. Although not grouped under the same cellular
process by MetaCore, all of these pathways are implicated
in similar mechanisms like cell cycle regulation, apoptosis/
survival, and cytoskeleton remodeling. Many of the signif-
icantly correlating genes within these pathways are shared
and include forkhead box O3, Fas ligand, the 14-3-3 gene,
D.G.A.J. Hebels et al. / Cancer Letters 309 (2011) 1–10 7cyclin D3, and actin the ﬁrst three of which are positively
correlated with ATNC levels and the remaining two are
negatively correlated (results not shown). This could, in
theory, result in stimulation of apoptosis and inhibition
of cell cycle progression following the induction of DNA
damage by NOCs, as based on information on these genes
obtained from Entrez Gene at the NCBI (http://www.ncbi.
nlm.nih.gov/sites/entrez?db=gene). Pathways speciﬁcally
implicated in apoptosis or cell cycle regulation were not
identiﬁed. This is not surprising considering that NOC
levels reached in the human colon are unlikely to cause en-
ough damage to strongly induce a cell cycle block or apop-
tosis in order to either repair damage or prevent the cell
from dividing [10]. However, since these modiﬁcations
provide evidence for a genotoxic effect of NOCs in colon
tissue, it could be hypothesized that prolonged exposure
to NOCs results in an accumulation of DNA damage over
time. This would be especially relevant in people who dis-
play a strong endogenous formation of NOCs in the colon
throughout life. In the classic genetic model proposed by
Fearon and Vogelstein [22], a continuously high exposure
could facilitate the development of CRC by accelerating
the carcinogenic transformation of colon cells.
The set of signiﬁcantly correlating ATNC genes was sub-
sequently analyzed for its involvement in signiﬁcantly
modulated GO processes and the top 10 contained six pro-
cesses involved in chromatin assembly/disassembly which
thus represents an important process. We therefore ex-
plored in depth signiﬁcantly correlating genes in the six
most strongly deregulated processes (Chromatin assembly)
in a network analysis, in order to visualize their interac-
tions. As shown in Fig. 1, signiﬁcantly correlating genes
in the Chromatin assembly process all encode histones or
proteins involved in chromatin organization. Regulation
of the chromatin structure plays an essential role in con-
trolling gene expression and these results suggest that
NOCs inﬂuence gene expression by histone modiﬁcations.
NOCs have been described to induce chromatin damage,
resulting in inhibition of protein and nuclear RNA synthe-
sis, and to cause imbalances in histone and non-histone
proteins, but only at high concentrations in animal models
[23–26]. NOC-induced alkylation of these proteins could
affect their interaction with DNA and inﬂuence gene
expression levels [23,27]. Histone methylation, for exam-
ple, promotes heterochromatin formation resulting in gene
silencing [28] and it is possible that (methylating) NOCs
inﬂuence the expression of genes through such epigenetic
mechanisms. Promotion of heterochromatin formation is
supported by our data since all positively correlating his-
tone genes are variants of histone H2A and H2B which
are core components of heterochromatic nucleosomes
[29]. Histones H1b and H3.1 and the BRM protein are also
involved in heterochromatin formation, but they were neg-
atively correlated with ATNC levels, while the function of
the negatively correlating gene HP1-BP74 is not known.
Possibly related to this is the discovery that alkylating
DNA damage, and formation of O6-methylguanine in par-
ticular, as may be caused by NOCs, is linked to the modu-
lation of gene expression by both inhibiting and
promoting the action of maintenance methylases on adja-
cent cytosine bases which is likely to result in chromatinmodiﬁcations [30–32]. It is also possible that the up regu-
lation of histone genes represents a compensatory synthe-
sis of new histones to replace damaged ones. Since this
would require remodeling of the nucleosome complex,
gene expression may also be inﬂuenced. In the past two
decades, histone modiﬁcation following NOC exposure
has not received much attention in literature and these re-
sults may be a starting point for new investigations into
the relation between NOCs and chromatin assembly in
relation to gene expression changes.
Alterations in the expression of histone and chromatin
remodeling genes in relation to NOC exposure has, to our
knowledge, never been shown before. Given the estab-
lished role of epigenetic modiﬁcations in chromatin in
the development of cancer by inﬂuencing the expression
of tumor-suppressor genes and oncogenes, the discovery
of these modiﬁcations in humans exposed to physiological
NOC concentrations under daily life circumstances, may be
of relevance with regard to carcinogenic risks associated
with NOC exposure [33]. Since the colon is one of the main
targets of NOCs, the histone modiﬁcations we identiﬁed
could represent a novel epigenetic mechanism in the
development of CRC following NOC exposure, for instance
by providing a growth advantage through the silencing of
tumor suppressor genes.
A few studies have demonstrated an increased nitrosa-
tion in inﬂammatory environments, including the colon of
patients with IBD who thus form an interesting population
to study NOC-associated gene expression changes [13,14].
Although there is a substantial amount of evidence that in-
creased oxidative stress levels associated with chronic
inﬂammation contribute to neoplastic transformation in
IBD patients [34], NOCs may also play a signiﬁcant role.
As demonstrated by the fecal calprotectin levels (Table
1), IBD patients indeed had a higher level of colonic inﬂam-
mation compared to IBS controls, conﬁrming that IBS pa-
tients form a suitable control group [35,36]. However, no
signiﬁcant differences with respect to fecal ATNC levels
were found between both groups, nor was there a signiﬁ-
cant correlation between calprotectin and ATNC levels,
indicating that in this study colonic inﬂammation did not
signiﬁcantly stimulate the formation of fecal NOCs. In a
previous study we did ﬁnd a signiﬁcant increase in one
of the most important excreted fecal NOCs (N-nitrosodim-
ethylamine) in IBD patients compared to healthy controls
[13], which may be explained by the inclusion of more se-
vere and hospitalized IBD cases in that particular study.
Food diaries recorded by all subjects showed that the aver-
age intake of most dietary components was not signiﬁ-
cantly different between IBD and IBS patients, except for
total fat, saturated fat, cholesterol, zinc, folic acid, and vita-
min B12, which were all signiﬁcantly higher in the IBD
group and can be ascribed to differences in gender ratio be-
tween groups (Table 3). It is thus unlikely that these die-
tary factors inﬂuence NOC formation. The most important
dietary components with regard to stimulation or inhibi-
tion of endogenous nitrosation are animal protein, vitamin
C and E, and possibly iron [37,38], none of which were dif-
ferent between groups. We therefore conclude that inter-
individual differences in dietary patterns are not account-
able for the absence of signiﬁcantly different fecal ATNC
8 D.G.A.J. Hebels et al. / Cancer Letters 309 (2011) 1–10levels between the study populations, but IBD severity may
be.
At the gene expression level, IBD patients and controls
did demonstrate a distinctive response, as shown by the
PCA plot where IBD and IBS patients form two groups with
only a limited degree of overlap (Fig. 2). This is in agree-
ment with several studies showing that the gene expres-
sion proﬁle in colon biopsies from ulcerative colitis
patients is different from non-inﬂamed controls [39–42].
Differentially modiﬁed genes between IBD patients and
controls were strongly involved in the immune response,
and in particular biological pathways regulating the
inﬂammatory response, including many cytokine signaling
pathways (Table 4). (L)-Arginine metabolism, which is
essential in the production of NO through the activity of
iNOS, was also signiﬁcantly modulated. The iNOS gene,
which is activated by cyclooxygenase 2 (COX-2) and many
cytokines [43,44], was signiﬁcantly up regulated in IBD pa-
tients, as was COX-2 (results not shown). This is expected
to lead to NO production which in turn stimulates the for-
mation of pro-inﬂammatory mediators by increasing the
expression of COX-2, thus creating a positive feedback loop
[45]. Cytokine production in ulcerative colitis patients is
one of the main factors contributing to the ongoing relaps-
ing activation of the mucosal immune system in the gut
which fails to be resolved and leads to a persistent state
of chronic inﬂammation [46,47]. Indeed, many pro-inﬂam-
matory genes were found to be up regulated in the im-
mune response pathways, including several cytokines
and cytokine receptors, which is especially interesting
since the biopsies were taken from visually non-inﬂamed
tissue in the colon. This suggests that a much larger part
of the colon than only the visually inﬂamed section is in
a (low) state of inﬂammation. Similar observations were
made in tissue from ulcerative colitis patients in remission
[39] and it is possible that, even in the absence of an
inﬂammatory state, the mRNA expression pattern in colon
tissue from IBD patients facilitates a relapse in inﬂamma-
tion following the right trigger.
In addition to the strong immune response modiﬁca-
tions, a large number of development pathways were dif-
ferentially modulated between IBD patients and controls.
JAK/STAT signaling pathways are particularly strongly rep-
resented which is not surprising considering the essential
role of these pathways in cytokine signaling [48,49]. JAK/
STAT signaling also plays an important role in regulating
growth, survival, and differentiation and modiﬁcations in
these pathways could therefore inﬂuence the carcinogenic
process in IBD patients. Epithelial cell turn-over, for exam-
ple, is increased in the colonic IBD mucosa compared to
normal tissue through the actions of CDKN1A which is reg-
ulated by JAK/STAT signaling [50,51]. In combination with
the DNA damaging and mutagenic factors present in the
inﬂammatory environment, this provides the ideal circum-
stances for stimulation of the carcinogenic process.
The difference in the transcriptomic proﬁle between
IBD and IBS subjects raises the question whether the corre-
lation analysis with ATNC levels discussed earlier is war-
ranted. As discussed above, the difference in the
transcriptomic proﬁle between IBD and IBS patients can
most likely be attributed to the difference in colonicinﬂammatory state since there was no signiﬁcant differ-
ence in fecal ATNC levels between both groups. In addition,
both IBD and IBS subjects are exposed to NOCs as demon-
strated by their presence in the fecal matter of both groups
with similar percentages of samples above the detection
limit (Table 1). The transcriptomic difference between
IBD and IBS subjects and the absence of a difference in fecal
NOC excretion can thus be considered as independent par-
allel events. Although the gene expression proﬁle associ-
ated with IBD status could introduce more noise at the
transcriptome level, the NOC excretion-associated tran-
scriptomic proﬁle is likely to represent a gene expression
pattern that is NOC-speciﬁc regardless of the inﬂammatory
state in the colon.
Overall, we conclude that, although inﬂammation
apparently did not provide a statistically reliable model
for increased nitrosation in this study, gene expression
modiﬁcations were identiﬁed that clearly increase the cur-
rent understanding of IBD pathophysiology. More impor-
tantly, by speciﬁcally relating gene expression changes to
fecal ATNC levels, we have identiﬁed NOC exposure-associ-
ated transcriptomic responses that indicate that physiolog-
ical NOC concentrations may potentially induce DNA
damage and chromatin modiﬁcations in human colon tis-
sue. Since both effects are linked with carcinogenicity, fur-
ther research into NOC-speciﬁc DNA aberrations and
chromatin modiﬁcations seems relevant and is needed to
support these ﬁndings. This may be especially important
for IBD patients who are already at an increased risk of
developing CRC. This is the ﬁrst study to analyze the tran-
scriptomic response in the human colon in relation to NOC
exposure thereby shedding light on the possible role of
NOCs in human CRC development.
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